Study: Levofloxacin induced least toxicity, apoptosis

Article

In a study performed to evaluate and compare preserved versus unpreserved fluoroquinolone antibiotics, cell culture assays demonstrated some degree of toxicity and elevated induction of apoptosis in each of three commercially available topical ocular fluoroquinolone antibiotics, according to one expert.

Fort Lauderdale, FL-In a study performed to evaluate and compare preserved versus unpreserved fluoroquinolone antibiotics, cell culture assays demonstrated some degree of toxicity and elevated induction of apoptosis in each of three commercially available topical ocular fluoroquinolone antibiotics, according to Seth P. Epstein, MD, who presented a poster on his work with colleagues at the annual meeting of the Association for Research in Vision and Ophthalmology.

Of the three, nonpreserved levofloxacin ophthalmic solution 1.5% (Iquix, Santen/Vistakon Pharmaceuticals) induced the least toxicity and apoptosis, followed closely by nonpreserved moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon Laboratories), while gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan), which is preserved with 0.005% benzalkonium chloride (BAK), had the greatest levels of both toxicity and apoptosis, said Dr. Epstein, assistant professor of ophthalmology, Mount Sinai School of Medicine, New York, NY.

"There's been a great deal in the literature about the toxicity of BAK," Dr. Epstein said. "Previous work in our lab has determined that of the five classes of preservatives that are in use, BAK is one of the most toxic. It also is one of the most commonly used.

In this study, the investigators evaluated the toxicity and apoptosis induced by the antibiotics using a cell culture model consisting of an MTT (method of transcriptional and translational) cytotoxicity assay and a TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) apoptosis assay. Preconfluent immortalized conjunctival and human corneal epithelial cells were each incubated with the three commercial antibiotic preparations.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
© 2025 MJH Life Sciences

All rights reserved.